127 related articles for article (PubMed ID: 1374818)
21. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
22. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
23. [Tumor markers for ovarian cancers].
Aoki D; Kataoka F; Susumu N; Nozawa S
Nihon Rinsho; 2004 Oct; 62 Suppl 10():496-502. PubMed ID: 15535295
[No Abstract] [Full Text] [Related]
24. [The present and the future of tumor markers].
Nozawa S
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):883-9. PubMed ID: 1680941
[TBL] [Abstract][Full Text] [Related]
25. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
26. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
27. [A case of thymic cyst showing elevated CEA, SLX and CA125 levels in the cystic fluid associated with non-invasive thymoma].
Gotoh T; Tanaka T; Tsujimoto S; Toda S; Hashikura H; Arimoto T; Iwasaki Y; Nakamura T; Nakagawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Apr; 32(4):364-9. PubMed ID: 7913733
[TBL] [Abstract][Full Text] [Related]
28. [Clinical relevance of tumor markers for follow-up and therapy planning in ovarian cancer].
Böhm W; Lücke R; Ertle B; Benz R; Deinert S
Arch Gynecol Obstet; 1989; 245(1-4):640-2. PubMed ID: 2802749
[No Abstract] [Full Text] [Related]
29. Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age.
Var T; Tonguc EA; Ugur M; Altinbas S; Tokmak A
Bratisl Lek Listy; 2012; 113(2):95-8. PubMed ID: 22394039
[TBL] [Abstract][Full Text] [Related]
30. Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System.
Christenson RH; Cervelli DR; Sterner J; Bachmann LM; Rebuck H; Gray J; Kelley WE
Clin Biochem; 2011 Sep; 44(13):1128-1136. PubMed ID: 21704611
[TBL] [Abstract][Full Text] [Related]
31. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
Zhang F; Zhang ZL
Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
33. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
34. [New clinical tests: current status of tumor markers].
Imai K; Taniuchi A
Nihon Naika Gakkai Zasshi; 1993 Apr; 82(4):554-7. PubMed ID: 7688018
[No Abstract] [Full Text] [Related]
35. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of serum CA130 in patients with lung cancer].
Matsubara Y; Shiota T; Ishida H; Hanawa T; Yagi K; Kosaba S; Hatakenaka R; Funatsu T; Ikeda S
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1557-65. PubMed ID: 2572655
[TBL] [Abstract][Full Text] [Related]
37. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
38. Significance of CEA, AFP, SP1 and HCG as tumor markers in ovarian carcinoma.
Pulay T; Csömör S; Mészáros K; Szarka G; Csabay L; Szinnyai A
Neoplasma; 1987; 34(5):595-600. PubMed ID: 2447510
[TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
40. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
Kimura E; Kobayashi S; Terashima Y
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
